GENB earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.79. Updated 2026-07-23.
Generate Biomedicines (GENB) Research Hub
Generate Biomedicines (GENB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.72 USD (+1.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.79, market cap 1.79B. This hub links to the full technical, earnings and options research available for GENB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.72 USD (+1.29%) |
| 52-week range | 12.49 USD – 22.67 USD |
| Trend regime | Range |
| 14-day RSI | 54.5 (Neutral) |
| Trailing P/E | -2.79 |
| Market cap | 1.79B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for GENB
Covered Call on GENB: how it works, illustrative setup around the real 15.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GENB: how it works, illustrative setup around the real 15.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GENB: how it works, illustrative setup around the real 15.72 USD price, max profit/loss, breakeven and when to use it. Educational.
GENB technical analysis: range, last 15.72 USD, RSI 54.5, 52w range 12.49 USD–22.67 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GENB in?
Generate Biomedicines (GENB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GENB in an uptrend or downtrend?
As of 2026-09-11, GENB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GENB's trailing P/E ratio?
GENB's trailing P/E is -2.79, with a market cap of 1.79B. See the earnings research page for full valuation detail.
When does GENB next report earnings?
GENB is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.48 USD.